A study was conducted of the circadian hormonal and metabolic patterns of 10 type I (insulin dependent) uraemic diabetic patients after pancreas and renal transplantation. A single 24 hour profile was obtained in each patient following as closely as possible his or her normal daily routine two to 15 months after transplantation. None of the patients were using insulin at the time of the study. Compared with a group of six normal subjects the transplant recipients had mildly raised blood glucose concentrations, hyperinsulinaemia between meals and at night, delayed postprandial insulin peaks, mild hyperketonaemia, and normal blood lactate and plasma glucagon concentrations.
Introduction
The correction of metabolic abnormalities in type I (insulin dependent) diabetes depends on appropriate insulin replacement, ideally by means of a pancreas transplant able to regulate insulin production. In man this has been attempted only by transplanting the whole pancreas or a segment of it, transplantation of isolated islets having proved unsuccessful for technical and immunological reasons.' -3 Reports show that successful pancreas transplants lead to the disappearance of insulin dependence and of the clinical signs and symptoms of diabetes (hyperglycaemia, glycosuria, ketosis, polyuria, polydipsia). [4] [5] [6] [7] We have found that the insulin response to acute secretory stimuli is restored after pancreas transplantation.8-10 Nevertheless, the resulting hormonal and metabolic features have not been investigated.
routines.
Patients and methods
We studied 10 type I diabetic patients who were treated by simultaneous cadaveric donor pancreas and kidney transplantation. Table I summarises their clinical characteristics. All had been in end stage renal failure due to diabetic nephropathy and nine were receiving haemodialysis before transplantation; all had received laser photocoagulation for severe retinopathy, three of them being blind at the time of transplantation; and all had severe somatic and autonomic diabetic neuropathy. Residual f cell function before transplantation was nil or minimal, the plasma C peptide concentration being < 0-02 nmol/l (<0-06 ng/ml) fasting or after a mixed meal. At the time of investigation all patients had normal fasting blood glucose values, were independent of insulin, and had satisfactory renal graft function (table I) .
Transplantation-In each case the pancreas and renal grafts were transplanted simultaneously from the same cadaveric donor using a technique previously described." Briefly, pancreatic exocrine secretion was suppressed by injecting neoprene (a liquid rubber which hardens on contact with the pancreatic juice) into the ductal system. In nine cases the pancreatic graft was segmental (body and tail), and in one case the whole pancreas was transplanted. Pancreas 
Results
Table II and the figure show the mean 24 hour values, and their variations, for blood glucose, serum free insulin, plasma glucagon, blood lactate, and ,l-hydroxybutyrate. Mean blood glucose concentration in the transplant group was within the normal range at 0700 after an overnight fast (5-2 (SEM 0-18) v 5-3 (0-23) mmol/l in the controls (94-3 (3 30) v 95-3 (4'25) mg/100 ml); NS) and was slightly higher than the values observed in the normal subjects for the rest of the day (6'5 (0-19) v 5-2 (0 17) mmol/l (118 0 (3 5) v 93 8 (3 1) mg/100 ml); p < 0-01). The circadian glucose oscillations observed in the transplant recipients were similar to those observed in the normal subjects and, on average, did not exceed 7 9 mmol/l (142 mg/100 ml), although on two occasions in two patients values above 10-0 mmol/l (180 mg/ 100 ml) were observed (10 4 mmol/l (187 mg/100 ml) at 2400 in case 3; 13 3 mmol/l (239 mg/100 ml) at 2100 in case 8). Lower mean glycaemic values were observed in the two patients (cases 1 and 4) treated with cyclosporin only (5 9 (SEM 0 15) and 6-1 (0 33) mmol/l (106 8 (2-7) and 109 7 (5-9) mg/100 ml), respectively) compared with those receiving steroids as part of the immunosuppressive treatment (6-7 (0-21) mmol/l; 1210 (3-8) mg/100 ml).
The M value of the transplant recipients was 4-62 (SEM 0 75). The mean 24 hour serum free insulin concentrations in the transplant group were higher than those observed in the controls (31-0 (SEM 3 0) v 16-9 (1-8) mU/l; p <001), with persistent hyperinsulinaemia between meals and at night. Insulin secretion peaks in response to meals were delayed in the transplant group compared with controls (0900 v 0800 after breakfast, 1500 v 1400 after lunch, and 2000 v 1900 after dinner, respectively).
The mean blood 3-hydroxybutyrate concentrations over the 24 hours were on average higher in the transplant group than in the controls (331-9 (SEM 80 2) v 113 9 (18-9) smol/l (34-6 (8 3) v 11-9 (2-0) jtg/ml), respectively), although the wide variability within the transplant group dsd not produce any statistical significance. The pattern of the 24 hour variations was the same in the two groups, however, and was characterised by a progressive increase at night and between meals, followed by a decrease after meals.
The physiology of the pancreas graft, which is heterotopic and denervated, together with the immunosuppressive treatment and relatively impaired renal function might be responsible for minor differences in hormonal and metabolic patterns. Results comparable to ours have been described in non uraemic type I diabetic patients treated with artificial endocrine pancreas; continuous subcutaneous, intravenous, or intraperitoneal insulin infusions; and intensified conventional insulin treatments. [31] [32] [33] [34] [35] Pancreas transplantation seems an ethical proposition in type I diabetic patients undergoing kidney transplantation for chronic renal failure and in whom immunosuppression is to be used. In these cases pancreas transplantation, when successful, leads to the restoration of normal metabolic homoeostasis without hormone replacement.
SHORT REPORTS
Oral cholestyramine increases elimination of warfarin after overdose Warfarin overdose often requires a long period in hospital because of the prolonged duration of action of the drug. We describe how oral cholestyramine may speed clearance and reduce the period of hospital stay.
Case history A 25 year old man was admitted one hour after taking an overdose of an unknown amount of warfarin, 10 dextropropoxyphene tablets, and alcohol. He had been run over by a fire engine one year previously and received warfarin for two months for a subsequent pulmonary embolus. Clinical findings were normal but he refused gastric lavage or emesis. His paracetamol concentration was 53 mg/l after four hours and his serum alcohol concentration 37-5 mmol/l (173 mg/100 ml). Liver function values were normal throughout, although his British comparative ratio (international normalised ratio) (BCR (INR)) on admission was 1-3. He was given vitamin K 10 mg intramuscularly and then oral vitamin K 10 mg daily (figure). Two days later his BCR had risen to 9-2 and he was given a further 10 mg of vitamin K intramuscularly. Oral vitamin K (10 mg) continued to be administered, but after a further two days his BCR had risen to 8-8. Oral cholestyramine (4 g four times a day) was started and vitamin K (10 mg daily) continued intravenously. His BCR remained between 1-5 and 1-7 for the four days of his hospital stay and he did not develop bruising or bleeding at any time.
Plasma warfarin concentrations were measured by high performance liquid chromatography.' The concentration fell log linearly from 13 mg/l six hours after the overdose with a half life of elimination of 53 hours. After cholestyramine the plasma warfarin concentration continued to decline log linearly but with a half life of 33 hours.
Comment
In a report of a patient taking 250 mg warfarin Bjornsson and Blaschke initially administered vitamin K intravenously but then gave oral vitamin K with good response when the prothrombin time rose three days later.2 In our patient repeated oral doses of vitamin K (10 mg daily) failed to prevent steep rises in the BCR. Park and coworkers showed that bioavailability of oral vitamin K is low and very variable (10-63%).3 We therefore concur with the recommendations of Bjomsson and Blaschke that vitamin K should be given parenterally,2 although we do not agree that it must be given three to five times daily. In our patient a single dose of 10 mg vitamin K parenterally was enough to bring the BCR down within 24 hours on two separate occasions, and this dose given intramuscularly (if the BCR is less than 2 0) or by slow intravenous injection on a twice daily basis should be sufficient in most circumstances. The exact dose and frequency should be governed by the BCR.
